Examine Safety and Immune Responses of GSK 257049 Vaccine When Administered to Infants Living in a Malaria-endemic Region

PHASE2CompletedINTERVENTIONAL

Enrollment

214

Participants

Timeline

Start Date

August 23, 2005

Primary Completion Date

December 27, 2007

Study Completion Date

December 27, 2007

Conditions

Malaria

Interventions

BIOLOGICAL

RTS,S/AS02D

3-dose intramuscular injection in the thigh

BIOLOGICAL

TETRActHib™

3-dose intramuscular injection in the thigh.

BIOLOGICAL

Engerix-B®

3-dose intramuscular injection in the thigh.

Trial Locations (1)

GSK Investigational Site, Maputo